Reporting from ASH 2018, Umberto Vitolo first discusses the results from the FLYER trial that explored de-escalation of standard treatment in young, low risk DLBCL patients. He also comments on results from everyday clinical practice in the US about CAR-T cell therapy, which are very similar with what has been observed in the clinical trials setting.

Oncology Meeting Resources

Major Sponsors

AstraZeneca Bristol-Myers Squibb MSD Servier

Main Sponsors

Amgen Astellas Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo ipsen Janssen Novartis Roche